Strategic Communications and Marketing News Bureau

NSF funds new iBioFoundry at Illinois

CHAMPAIGN, Ill. — A newly funded U.S. National Science Foundation iBioFoundry at the University of Illinois Urbana-Champaign will build on more than a decade of research at the U. of I. to integrate synthetic biology, laboratory automation and artificial intelligence to advance protein and cellular engineering. This is one of five new biofoundries to be established in the U.S. 

According to the NSF, these facilities will “spur innovation, provide tools and technologies to researchers and help advance biology, biotechnology and the broader science, technology, engineering and math enterprise.” 

Each biofoundry will focus on a different area of biology or biotechnology, said U. of I. chemical and biomolecular engineering professor Huimin Zhao, who will lead the NSF iBioFoundry. The Illinois facility will expand the use of automated systems, machine learning and AI to promote and optimize advances in synthetic biology, biotechnology and genomics. 

Previous efforts at the U. of I. have led to major advances in integrating these elements, Zhao said. Earlier milestones include the development of BioAutomata, an AI-driven, robotic biomanufacturing platform that uses living cells to produce useful chemicals; and FAST-RiPPs, an automated platform for discovering new bioactive compounds. In 2014, Illinois researchers established iBioFab, a facility at the Carl R. Woese Institute for Genomic Biology that supports the efficient design, fabrication, validation and analysis of genetic constructs and organisms.

“The NSF iBioFoundry will serve as a hub for innovation, bringing together researchers, industry experts and policymakers to foster collaboration and accelerate the development of sustainable biomanufacturing processes,” Zhao said. “By centralizing resources and expertise, it will streamline the creation of new bio-based products and technologies, ranging from renewable chemicals to advanced medical treatments.”

Another key focus of the NSF iBioFoundry will be to share its capabilities with “a diverse community of external users who will work to solve important scientific problems through a peer-reviewed, competitive proposal process,” Zhao said. “It also will be an open ecosystem of disruptive thinking, education and community engagement that will revolutionize the way biology is taught and train the next generation workforce in biology, artificial intelligence and robotics.”

The total NSF award to Illinois is $15 million for six years, Zhao said. 

Zhao also is a professor in the IGB, a professor of bioengineering, of chemistry and of biomedical and translational sciences in the Carle Illinois College of Medicine. He is a member of the Cancer Center at Illinois. Chemical and biomolecular engineering is in the College of Liberal Arts and Sciences and ChBE and bioengineering are in The Grainger College of Engineering

Editor’s note:   

To reach Huimin Zhao, email zhao5@illinois.edu.  

For more information about the NSF biofoundries, see:
NSF invests in BioFoundries to drive advances across science and engineering

Read Next

Engineering Tilted image of used batteries.

Study shows new hope for commercially attractive lithium extraction from spent batteries

A new study shows that lithium — a critical element used in rechargeable batteries and susceptible to supply chain disruption — can be recovered from battery waste using an electrochemically driven recovery process. The method has been tested on commonly used types of lithium-containing batteries and demonstrates economic viability with the potential to simplify operations, minimize costs and increase the sustainability and attractiveness of the recovery process for commercial use.

Health and Medicine Research team in the lab.

Study: A cellular protein, FGD3, boosts breast cancer chemotherapy, immunotherapy

CHAMPAIGN, Ill. — A naturally occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a preclinical drug known as ErSO, researchers report. The protein, FGD3, contributes to the rupture of cancer cells disrupted […]

Arts Photo from "Anastasia: The Musical" showing the Romanov family in period costumes.

Lyric Theatre’s production of “Anastasia: The Musical” tells story of loss, survival and reinvention

CHAMPAIGN, Ill. — The Lyric Theatre’s production of “Anastasia: The Musical” is a story with romance and mystery, an appealing score and several big dance numbers. It also is a story of loss, survival and reinvention. The musical opened on Nov. 11 and will be performed Nov. 13-15 at Krannert Center for the Performing Arts. […]

Strategic Communications and Marketing News Bureau

507 E. Green St
MC-426
Champaign, IL 61820

Email: stratcom@illinois.edu

Phone (217) 333-5010